Search

Your search keyword '"MARCATILI M."' showing total 7 results
Start Over Author "MARCATILI M." Publisher mdpi
7 results on '"MARCATILI M."'

1. Clinical Markers of Panic and Generalized Anxiety Disorder: Overlapping Symptoms, Different Course and Outcome

Author

Caldiroli, A, Colzani, L, Capuzzi, E, Quitadamo, C, La Tegola, D, Surace, T, Russo, S, Capetti, M, Leo, S, Tringali, A, Marcatili, M, Zanelli Quarantini, F, Colmegna, F, Dakanalis, A, Buoli, M, Clerici, M, Caldiroli A., Colzani L., Capuzzi E., Quitadamo C., La Tegola D., Surace T., Russo S., Capetti M., Leo S., Tringali A., Marcatili M., Zanelli Quarantini F., Colmegna F., Dakanalis A., Buoli M., Clerici M., Caldiroli, A, Colzani, L, Capuzzi, E, Quitadamo, C, La Tegola, D, Surace, T, Russo, S, Capetti, M, Leo, S, Tringali, A, Marcatili, M, Zanelli Quarantini, F, Colmegna, F, Dakanalis, A, Buoli, M, Clerici, M, Caldiroli A., Colzani L., Capuzzi E., Quitadamo C., La Tegola D., Surace T., Russo S., Capetti M., Leo S., Tringali A., Marcatili M., Zanelli Quarantini F., Colmegna F., Dakanalis A., Buoli M., and Clerici M.

Abstract

Generalized Anxiety Disorder (GAD) and Panic Disorder (PD) share underlying neurobiological mechanisms and several clinical features which, with medical comorbidities, may increase misdiagnosis and delay proper treatment. The aim of the study was to evaluate the association between clinical/socio-demographic markers and GAD/PD diagnosis. Outpatients (N = 290) with PD or GAD were identified in mental health services in Monza and Milan (Italy). Descriptive analyses and a binary logistic regression model were performed. Post-onset psychiatric (p = 0.05) and medical (p = 0.02) multiple co-morbidities were associated with GAD; treatment with selective serotonin reuptake inhibitors (SSRIs) was associated with PD, while GAD diagnosis was associated with treatment with atypical antipsychotics or GABAergic drugs (p = 0.03), as well as psychodynamic psychotherapy (p < 0.01). Discontinuation of the last pharmacological treatment was associated with GAD diagnosis rather than the PD one (p = 0.02). GAD patients may have a worse prognosis than PD patients because of more frequent multiple co-morbidities, relapses and poorer treatment compliance. The different treatment approaches were consistent with the available literature, while the association between GAD and psychodynamic psychotherapy is an original finding of our study. Further studies on larger samples are necessary to better characterize clinical factors associated with GAD or PD.

Published
2023

2. Possible Use of Minocycline in Adjunction to Intranasal Esketamine for the Management of Difficult to Treat Depression following Extensive Pharmacogenomic Testing: Two Case Reports

Author

Marcatili, M, Borgonovo, R, Cimminiello, N, Cornaggia, R, Casati, G, Pellicioli, C, Maggioni, L, Motta, F, Redaelli, C, Ledda, L, Pozzi, F, Krivosova, M, Pagano, J, Nava, R, Colmegna, F, Dakanalis, A, Caldiroli, A, Capuzzi, E, Benatti, B, Dell’Osso, B, Bertola, F, Villa, N, Piperno, A, Ippolito, S, Appollonio, I, Sala, C, Conti, L, Clerici, M, Marcatili M., Borgonovo R., Cimminiello N., Cornaggia R. D., Casati G., Pellicioli C., Maggioni L., Motta F., Redaelli C., Ledda L., Pozzi F. E., Krivosova M., Pagano J., Nava R., Colmegna F., Dakanalis A., Caldiroli A., Capuzzi E., Benatti B., Dell’Osso B., Bertola F., Villa N., Piperno A., Ippolito S., Appollonio I., Sala C., Conti L., Clerici M., Marcatili, M, Borgonovo, R, Cimminiello, N, Cornaggia, R, Casati, G, Pellicioli, C, Maggioni, L, Motta, F, Redaelli, C, Ledda, L, Pozzi, F, Krivosova, M, Pagano, J, Nava, R, Colmegna, F, Dakanalis, A, Caldiroli, A, Capuzzi, E, Benatti, B, Dell’Osso, B, Bertola, F, Villa, N, Piperno, A, Ippolito, S, Appollonio, I, Sala, C, Conti, L, Clerici, M, Marcatili M., Borgonovo R., Cimminiello N., Cornaggia R. D., Casati G., Pellicioli C., Maggioni L., Motta F., Redaelli C., Ledda L., Pozzi F. E., Krivosova M., Pagano J., Nava R., Colmegna F., Dakanalis A., Caldiroli A., Capuzzi E., Benatti B., Dell’Osso B., Bertola F., Villa N., Piperno A., Ippolito S., Appollonio I., Sala C., Conti L., and Clerici M.

Abstract

The advent of intra-nasal esketamine (ESK), one of the first so called fast-acting antidepressant, promises to revolutionize the management of treatment resistant depression (TRD). This NMDA receptor antagonist has proven to be rapidly effective in the short- and medium-term course of the illness, revealing its potential in targeting response in TRD. Although many TRD ESK responders are able to achieve remission, a considerable portion of them undergo a metamorphosis of their depression into different clinical presentations, characterized by instable responses and high recurrence rates that can be considered closer to the concept of Difficult to Treat Depression (DTD) than to TRD. The management of these DTD patients usually requires a further complex multidisciplinary approach and can benefit from the valuable contribution of new personalized medicine tools such as therapeutic drug monitoring and pharmacogenetics. Despite this, these patients usually come with long and complex previous treatments history and, often, advanced and sophisticated ongoing pharmacological schemes that can make the finding of new alternative options to face the current recurrences extremely challenging. In this paper, we describe two DTD patients—already receiving intranasal ESK but showing an instable course—who were clinically stabilized by the association with minocycline, a semisynthetic second-generation tetracycline with known and promising antidepressant properties.

Published
2022

3. Clinical Markers of Panic and Generalized Anxiety Disorder: Overlapping Symptoms, Different Course and Outcome

Author

Alice Caldiroli, Lia Colzani, Enrico Capuzzi, Cecilia Quitadamo, Davide La Tegola, Teresa Surace, Stefania Russo, Mauro Capetti, Silvia Leo, Agnese Tringali, Matteo Marcatili, Francesco Zanelli Quarantini, Fabrizia Colmegna, Antonios Dakanalis, Massimiliano Buoli, Massimo Clerici, Caldiroli, A, Colzani, L, Capuzzi, E, Quitadamo, C, La Tegola, D, Surace, T, Russo, S, Capetti, M, Leo, S, Tringali, A, Marcatili, M, Zanelli Quarantini, F, Colmegna, F, Dakanalis, A, Buoli, M, and Clerici, M

Subjects
generalized anxiety disorder, panic disorder, comorbidities, chronicity, outcome, anxiety disorders, comorbiditie, Medicine (miscellaneous), anxiety disorder
Abstract

Generalized Anxiety Disorder (GAD) and Panic Disorder (PD) share underlying neurobiological mechanisms and several clinical features which, with medical comorbidities, may increase misdiagnosis and delay proper treatment. The aim of the study was to evaluate the association between clinical/socio-demographic markers and GAD/PD diagnosis. Outpatients (N = 290) with PD or GAD were identified in mental health services in Monza and Milan (Italy). Descriptive analyses and a binary logistic regression model were performed. Post-onset psychiatric (p = 0.05) and medical (p = 0.02) multiple co-morbidities were associated with GAD; treatment with selective serotonin reuptake inhibitors (SSRIs) was associated with PD, while GAD diagnosis was associated with treatment with atypical antipsychotics or GABAergic drugs (p = 0.03), as well as psychodynamic psychotherapy (p < 0.01). Discontinuation of the last pharmacological treatment was associated with GAD diagnosis rather than the PD one (p = 0.02). GAD patients may have a worse prognosis than PD patients because of more frequent multiple co-morbidities, relapses and poorer treatment compliance. The different treatment approaches were consistent with the available literature, while the association between GAD and psychodynamic psychotherapy is an original finding of our study. Further studies on larger samples are necessary to better characterize clinical factors associated with GAD or PD.

Published
2023

4. Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review

Author

Antonios Dakanalis, Martina Capellazzi, Matteo Marcatili, Massimiliano Buoli, Alice Caldiroli, Massimo Clerici, Enrico Capuzzi, Fabrizia Colmegna, Ilaria Tagliabue, Francesco Mucci, Caldiroli, A, Capuzzi, E, Tagliabue, I, Capellazzi, M, Marcatili, M, Mucci, F, Colmegna, F, Clerici, M, Buoli, M, and Dakanalis, A

Subjects
Olanzapine, QH301-705.5, Cariprazine, Review, Lithium, Bioinformatics, Catalysis, Inorganic Chemistry, chemistry.chemical_compound, Depressive Disorder, Treatment-Resistant, augmentation, Medicine, Humans, Ziprasidone, Biology (General), Physical and Theoretical Chemistry, QD1-999, Molecular Biology, Spectroscopy, Brexpiprazole, psychopharmacology, Risperidone, business.industry, Organic Chemistry, General Medicine, medicine.disease, Antidepressive Agents, Buspirone, Computer Science Applications, Chemistry, Treatment‐resistant depression, chemistry, treatment-resistant depression, Quetiapine, Antidepressive Agents, Second-Generation, Aripiprazole, Anticonvulsants, Central Nervous System Stimulants, Ketamine, business, Treatment-resistant depression, medicine.drug
Abstract

Treatment resistant depression (TRD) is associated with poor outcomes, but a consensus is lacking in the literature regarding which compound represents the best pharmacological augmentation strategy to antidepressants (AD). In the present review, we identify the available literature regarding the pharmacological augmentation to AD in TRD. Research in the main psychiatric databases was performed (PubMed, ISI Web of Knowledge, PsychInfo). Only original articles in English with the main topic being pharmacological augmentation in TRD and presenting a precise definition of TRD were included. Aripiprazole and lithium were the most investigated molecules, and aripiprazole presented the strongest evidence of efficacy. Moreover, olanzapine, quetiapine, cariprazine, risperidone, and ziprasidone showed positive results but to a lesser extent. Brexpiprazole and intranasal esketamine need further study in real-world practice. Intravenous ketamine presented an evincible AD effect in the short-term. The efficacy of adjunctive ADs, antiepileptic drugs, psychostimulants, pramipexole, ropinirole, acetyl-salicylic acid, metyrapone, reserpine, testosterone, T3/T4, naltrexone, SAMe, and zinc cannot be precisely estimated in light of the limited available data. Studies on lamotrigine and pindolol reported negative results. According to our results, aripiprazole and lithium may be considered by clinicians as potential effective augmentative strategies in TRD, although the data regarding lithium are somewhat controversial. Reliable conclusions about the other molecules cannot be drawn. Further controlled comparative studies, standardized in terms of design, doses, and duration of the augmentative treatments, are needed to formulate definitive conclusions.

Published
2021

5. Negative-Pressure Wound Therapy (NPWT) in Horses: A Scoping Review.

Author

Cantatore F, Pagliara E, Marcatili M, and Bertuglia A

Abstract

Obtaining a healthy wound environment that is conductive to healing in horses can be challenging. Negative-pressure wound therapy (NPWT) has been employed in humans to enhance wound healing for decades. The existing evidence for the effectiveness of NPWT remains uncertain in equine medicine. The aim of this review is to investigate NPWT applications and benefits in horses. A scoping review was performed according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines for scoping reviews on three databases (PubMed, Web of Science-Thompson Reuters, and Wiley Online Library). Twenty-four manuscripts were considered. After removing duplicates, 17 papers underwent abstract screening. Of these, 16 + 1 (cited by others) were evaluated for eligibility according to PICOs, including no case reports/retrospective studies, four original articles, and three reviews. Fifteen manuscripts met the inclusion criteria. The focus of the articles was wound management; they included three reports of wounds communicating with synovial structures. Traumatic wounds and surgical-site infections are indications for NPWT. NPWT presents several advantages and few complications making it an attractive alternative to conventional wound management. However, randomized controlled trials should be performed to quantify the benefits and establish precise protocols in horses.

Published
2023
Full Text
View/download PDF

6. Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review.

Author

Caldiroli A, Capuzzi E, Tagliabue I, Capellazzi M, Marcatili M, Mucci F, Colmegna F, Clerici M, Buoli M, and Dakanalis A

Subjects
Anticonvulsants therapeutic use, Antidepressive Agents, Second-Generation therapeutic use, Buspirone therapeutic use, Central Nervous System Stimulants therapeutic use, Depressive Disorder, Treatment-Resistant psychology, Humans, Ketamine therapeutic use, Lithium therapeutic use, Antidepressive Agents therapeutic use, Depressive Disorder, Treatment-Resistant drug therapy
Abstract

Treatment resistant depression (TRD) is associated with poor outcomes, but a consensus is lacking in the literature regarding which compound represents the best pharmacological augmentation strategy to antidepressants (AD). In the present review, we identify the available literature regarding the pharmacological augmentation to AD in TRD. Research in the main psychiatric databases was performed (PubMed, ISI Web of Knowledge, PsychInfo). Only original articles in English with the main topic being pharmacological augmentation in TRD and presenting a precise definition of TRD were included. Aripiprazole and lithium were the most investigated molecules, and aripiprazole presented the strongest evidence of efficacy. Moreover, olanzapine, quetiapine, cariprazine, risperidone, and ziprasidone showed positive results but to a lesser extent. Brexpiprazole and intranasal esketamine need further study in real-world practice. Intravenous ketamine presented an evincible AD effect in the short-term. The efficacy of adjunctive ADs, antiepileptic drugs, psychostimulants, pramipexole, ropinirole, acetyl-salicylic acid, metyrapone, reserpine, testosterone, T3/T4, naltrexone, SAMe, and zinc cannot be precisely estimated in light of the limited available data. Studies on lamotrigine and pindolol reported negative results. According to our results, aripiprazole and lithium may be considered by clinicians as potential effective augmentative strategies in TRD, although the data regarding lithium are somewhat controversial. Reliable conclusions about the other molecules cannot be drawn. Further controlled comparative studies, standardized in terms of design, doses, and duration of the augmentative treatments, are needed to formulate definitive conclusions.

Published
2021
Full Text
View/download PDF

7. Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review.

Author

Capuzzi E, Caldiroli A, Capellazzi M, Tagliabue I, Marcatili M, Colmegna F, Clerici M, Buoli M, and Dakanalis A

Subjects
Administration, Intranasal, Antidepressive Agents administration & dosage, Depressive Disorder, Treatment-Resistant pathology, Humans, Ketamine administration & dosage, Secondary Prevention, Antidepressive Agents pharmacology, Depressive Disorder, Major drug therapy, Depressive Disorder, Treatment-Resistant drug therapy, Ketamine pharmacology
Abstract

Esketamine (ESK) has been approved as a rapid-acting intranasal treatment for treatment-resistant depression (TRD). Although existing studies have investigated the efficacy of ESK in the 4-week induction phase, our knowledge about long-term ESK efficacy remains poor. The aim of this systematic review was to summarize the available data on long-term ESK efficacy for TRD. A systematic search was performed including articles in English, up to 31 March 2021. The search found 7 relevant studies, involving 1024 adult TRD patients. Continuing treatment with ESK after the 4-week induction phase may be associated with stable efficacy in relapse prevention among TRD patients. Conversely, the long-term antidepressant effectiveness upon discontinuation of ESK might be limited, although data from three studies had a moderate to high risk of bias. Overall, the results on the effectiveness of this compound in the long term are mixed. According to our findings, ESK treatment should be continued following the induction phase to reach a stable efficacy in relapse prevention, while the long-term antidepressant and anti-suicidal effects of ESK after discontinuation are inconsistent. Currently, the level of proof of ESK efficacy in long-term TRD treatment remains low and more RCTs with larger sample sizes and active comparators are needed.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results